vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and DHT Holdings, Inc. (DHT). Click either name above to swap in a different company.
DHT Holdings, Inc. is the larger business by last-quarter revenue ($107.3M vs $62.1M, roughly 1.7× Cytek Biosciences, Inc.). DHT Holdings, Inc. runs the higher net margin — 41.7% vs -70.9%, a 112.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -24.5%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
DHT Holdings, Inc. is an independent international crude oil tanker operator that owns and manages a fleet of very large crude carriers. It offers marine transportation services for crude oil across major global trade routes, serving clients including leading oil producers, refineries, and commodity trading enterprises worldwide.
CTKB vs DHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $107.3M |
| Net Profit | $-44.1M | $44.8M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 44.2% |
| Net Margin | -70.9% | 41.7% |
| Revenue YoY | 8.1% | -24.5% |
| Net Profit YoY | -557.1% | 27.3% |
| EPS (diluted) | — | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | — | ||
| Q3 25 | $52.3M | $107.3M | ||
| Q2 25 | $45.6M | — | ||
| Q1 25 | $41.5M | — | ||
| Q4 24 | $57.5M | — | ||
| Q3 24 | $51.5M | $142.1M | ||
| Q2 24 | $46.6M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | $44.8M | ||
| Q2 25 | $-5.6M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | $35.2M | ||
| Q2 24 | $-10.4M | — | ||
| Q1 24 | $-6.2M | — |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | — | ||
| Q3 25 | -17.6% | 44.2% | ||
| Q2 25 | -23.3% | — | ||
| Q1 25 | -36.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | -8.2% | 29.7% | ||
| Q2 24 | -18.3% | — | ||
| Q1 24 | -23.9% | — |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | 41.7% | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | -27.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | 24.8% | ||
| Q2 24 | -22.4% | — | ||
| Q1 24 | -13.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0.22 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $81.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $1.1B |
| Total Assets | $461.5M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | $81.3M | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | — | ||
| Q3 24 | $162.3M | $73.8M | ||
| Q2 24 | $177.9M | — | ||
| Q1 24 | $168.8M | — |
| Q4 25 | $341.7M | — | ||
| Q3 25 | $378.6M | $1.1B | ||
| Q2 25 | $377.6M | — | ||
| Q1 25 | $379.6M | — | ||
| Q4 24 | $395.7M | — | ||
| Q3 24 | $385.5M | $1.0B | ||
| Q2 24 | $389.1M | — | ||
| Q1 24 | $392.6M | — |
| Q4 25 | $461.5M | — | ||
| Q3 25 | $494.9M | $1.4B | ||
| Q2 25 | $493.3M | — | ||
| Q1 25 | $482.6M | — | ||
| Q4 24 | $499.5M | — | ||
| Q3 24 | $491.2M | $1.5B | ||
| Q2 24 | $483.7M | — | ||
| Q1 24 | $492.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $60.9M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | — | ||
| Q3 25 | $-3.9M | $60.9M | ||
| Q2 25 | $108.0K | — | ||
| Q1 25 | $-125.0K | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $13.2M | $80.1M | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $4.0M | — |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 2.28× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
DHT
Segment breakdown not available.
